1-(2,4-difluorophenyl)urea | 145602-64-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2,4-difluorophenyl)urea
• 英文别名: 2,4-difluorophenylurea；(2,4-Difluorophenyl)urea
• CAS: 145602-64-8
• 化学式: C₇H₆F₂N₂O
• mdl: MFCD00025401
• 分子量: 172.134
• InChiKey: SBBRRSKIPTXBCO-UHFFFAOYSA-N

物化性质

• 沸点：
  218.0±30.0 °C(Predicted)
• 密度：
  1.457±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2,4-difluorophenyl)urea 在 乙醇 、 sodium 、 溶剂黄146 作用下， 生成 5-((3-fluoro-4-(6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yloxy)phenylamino)methylene)-1-(2,4-difluorophenyl)pyrimidine-2,4,6-trione
  参考文献：
  名称：

  Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors

  摘要：

  A series of novel quinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety were designed, synthesized, and evaluated for their c-Met kinase inhibitory activities and antiproliferative activities against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) in vitro. Most compounds showed moderate to excellent potency, with the most promising analogue 45 (c-Met half-maximal inhibitory concentration [IC50] = 1.15 nM) showing high selectivity versus 5 other tyrosine kinases, VEGFR-2, Flt-3, PDGFR-beta, c-Kit, and EGFR. Structure-activity relationship studies indicated that electron-donating groups on the phenyl ring at the 3-position of pyrimidine-2,4,6-trione were required to increase the electron density on the 5-(aminomethylene) pyrimidine-2,4,6-trione moiety. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.01.014
• 作为产物：
  描述：

  2,4-二氟苯基异氰酸酯 在 氨 、 水 作用下， 以 丙酮 为溶剂， 生成 1-(2,4-difluorophenyl)urea
  参考文献：
  名称：

  N-（3-苄氨基-2-氰基-3-甲基硫代丙烯酰基）-N'-（取代苯基）脲的合成及晶体结构

  摘要：

  将苯脲基引入传统的氰基丙烯酸酯骨架中，合成了一系列的N-（3-苄氨基-2-氰基-3-甲基硫代丙烯酰基）-N'-（取代的苯基）脲。所有化合物均为新化合物，其结构通过1 H NMR，13 C NMR和质谱分析确定。关键词：合成，氰基丙烯酸酯，苯脲衍生物。化学 Soc。埃塞俄比亚。2013，27（2），295-300。DOI：http：//dx.doi.org/10.4314/bcse.v27i2.15

  DOI：

  10.4314/bcse.v27i2.15

文献信息

• [EN] ANTIBACTERIAL BENZOIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDES BENZOIQUES ANTIBACTERIENS
  申请人：UPJOHN CO

  公开号：WO2004018428A1

  公开（公告）日：2004-03-04

  The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

  这项发明提供了抗菌剂和使用这些剂进行哺乳动物的消毒、卫生、防腐、消毒和治疗感染的方法。
• [EN] FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS<br/>[FR] COMPOSÉS D'URÉE TRICYCLIQUES CONDENSÉS COMME INHIBITEURS DE RAF KINASE ET/OU DE DIMÈRES DE RAF KINASE
  申请人：BEIGENE LTD

  公开号：WO2014206343A1

  公开（公告）日：2014-12-31

  Provided are certain fused tricyclic urea compounds and salts thereof, compositions thereof, and methods of use therefor.

  提供了某些融合的三环脲化合物及其盐、组合物以及使用方法。
• OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Braun Alain

  公开号：US20070149562A1

  公开（公告）日：2007-06-28

  The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

  本发明涉及根据本文所定义的式（I）的化合物，这些化合物是黑色素皮质素受体激动剂，涉及其制备以及在治疗或预防肥胖、糖尿病和可能影响两性的性功能障碍中的治疗用途，治疗心血管疾病，以及抗炎症用途或治疗酒精依赖症。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20210332045A1

  公开（公告）日：2021-10-28

  Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

  提供了一种化合物，可以抑制MALT1，并且预计作为预防或治疗癌症等疾病的药物是有用的。化合物由式(I)表示[其中每个符号如描述中所定义]，其盐，或其共晶体，水合物或溶剂化合物。
• Preventives and remedies for central nervous system diseases
  申请人：——

  公开号：US20030207863A1

  公开（公告）日：2003-11-06

  A prophylactic or therapeutic agent for central nervous system diseases based on amyloid &bgr;40 secretion inhibitory activity of a compound having urotensin II receptor antagonistic activity or a salt thereof.

  一种预防或治疗中枢神经系统疾病的药剂，基于一种具有尿泰松II受体拮抗活性或其盐的化合物对淀粉样蛋白β40分泌抑制活性。